ERBB2 and neoplasm: In HR-positive HER2-negative tumours, almost three quarters showed less than 10% TILs, whereas HER2-positive tumours and TNBCs showed higher amounts of TILs (55.4% and 72.2%, respectively, with more than 10% TILs) (see Figure 2).